Latest News

FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies
28th September, 2017
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one… READ MORE
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation
27th September, 2017
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European… READ MORE
FDA news : Cellular & Gene Therapy Guidances
FDA news : Cellular & Gene Therapy Guidances
2nd April, 2017
A useful resource of Cellular & Gene Therapy Guidance Documents READ MORE
EMA News
EMA News
2nd April, 2017
This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use… READ MORE
Gene Therapy of Liver Diseases
Gene Therapy of Liver Diseases
2nd April, 2017
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However,… READ MORE
Vivet Therapeutics raises €37.5 million in Series A financing round
Vivet Therapeutics raises €37.5 million in Series A financing round
1st April, 2017
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases READ MORE